Aging Brain Center, Institute for Aging Research, Hebrew SeniorLife, 1200 Centre Street, Boston, MA 02131, USA.
Ann Intern Med. 2012 Jun 19;156(12):848-56, W296. doi: 10.7326/0003-4819-156-12-201206190-00005.
Hospitalization, frequently complicated by delirium, can be a life-changing event for patients with Alzheimer disease (AD).
To determine risks for institutionalization, cognitive decline, or death associated with hospitalization and delirium in patients with AD.
Prospective cohort enrolled between 1991 and 2006 into the Massachusetts Alzheimer's Disease Research Center (MADRC) patient registry.
Community-based.
771 persons aged 65 years or older with a clinical diagnosis of AD.
Hospitalization, delirium, death, and institutionalization were identified through administrative databases. Cognitive decline was defined as a decrease of 4 or more points on the Blessed Information-Memory-Concentration test score. Multivariate analysis was used to calculate adjusted relative risks (RRs).
Of 771 participants with AD, 367 (48%) were hospitalized and 194 (25%) developed delirium. Hospitalized patients who did not have delirium had an increased risk for death (adjusted RR, 4.7 [95% CI, 1.9 to 11.6]) and institutionalization (adjusted RR, 6.9 [CI, 4.0 to 11.7]). With delirium, risk for death (adjusted RR, 5.4 [CI, 2.3 to 12.5]) and institutionalization (adjusted RR, 9.3 [CI, 5.5 to 15.7]) increased further. With hospitalization and delirium, the adjusted RR for cognitive decline for patients with AD was 1.6 (CI, 1.2 to 2.3). Among hospitalized patients with AD, 21% of the incidences of cognitive decline, 15% of institutionalization, and 6% of deaths were associated with delirium.
Cognitive outcome was missing in 291 patients. Sensitivity analysis was performed to test the effect of missing data, and a composite outcome was used to decrease the effect of missing data.
Approximately 1 in 8 hospitalized patients with AD who develop delirium will have at least 1 adverse outcome, including death, institutionalization, or cognitive decline, associated with delirium. Delirium prevention may represent an important strategy for reducing adverse outcomes in this population.
住院治疗常常会并发谵妄,这可能会使阿尔茨海默病(AD)患者的生活发生改变。
确定与 AD 患者住院和谵妄相关的住院治疗、认知能力下降或死亡的风险因素。
前瞻性队列研究,1991 年至 2006 年期间纳入马萨诸塞州阿尔茨海默病研究中心(MADRC)患者登记处。
社区。
771 名年龄在 65 岁及以上、临床诊断为 AD 的患者。
通过行政数据库确定住院治疗、谵妄、死亡和住院治疗情况。认知能力下降定义为Blessed 信息记忆浓度测试评分下降 4 分或 4 分以上。采用多变量分析计算调整后的相对风险(RR)。
771 名 AD 患者中,367 名(48%)住院治疗,194 名(25%)发生谵妄。未发生谵妄的住院患者死亡风险增加(调整 RR,4.7 [95%CI,1.9 至 11.6])和住院治疗风险增加(调整 RR,6.9 [CI,4.0 至 11.7])。发生谵妄后,死亡风险(调整 RR,5.4 [CI,2.3 至 12.5])和住院治疗风险(调整 RR,9.3 [CI,5.5 至 15.7])进一步增加。AD 患者发生住院治疗和谵妄时,认知能力下降的调整 RR 为 1.6(CI,1.2 至 2.3)。在住院 AD 患者中,21%的认知能力下降发生率、15%的住院治疗发生率和 6%的死亡率与谵妄有关。
771 名患者中有 291 名患者的认知结果缺失。进行了敏感性分析以测试缺失数据的影响,并使用综合结果来降低缺失数据的影响。
大约每 8 名住院治疗的 AD 患者中就有 1 名患者发生谵妄,谵妄至少会导致 1 种不良结局,包括死亡、住院治疗或认知能力下降,与谵妄相关。谵妄预防可能是减少该人群不良结局的重要策略。